Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Amortization of Deferred Charges (2020 - 2023)

Alx Oncology Holdings' Amortization of Deferred Charges history spans 2 years, with the latest figure at $64000.0 for Q4 2023.

  • For Q4 2023, Amortization of Deferred Charges changed N/A year-over-year to $64000.0; the TTM value through Dec 2023 reached $250000.0, changed N/A, while the annual FY2025 figure was $280000.0, 5.66% up from the prior year.
  • Amortization of Deferred Charges for Q4 2023 was $64000.0 at Alx Oncology Holdings, up from $63000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $118000.0 in Q3 2020 and bottomed at $61000.0 in Q1 2023.